Stereotaxis reports Q4 2025 revenue $8.6M (+36% YoY); guides FY2026 revenue >$40M

Stereotaxis, Inc.

Q4 2025 revenue $8.6M (+36% YoY); system rev $3.3M, recurring $5.3M.
Full year 2025 revenue $32.4M (+20% YoY); guidance for 2026 to surpass $40M.
Q4 net loss $5.5M vs $7.5M prior year; adjusted net loss $2.5M vs $3.6M.
Cash $13.4M, no debt; raised $3.1M in ATM offering at avg $3.17/share.
Key 2026 milestones: 5 GenesisX programs, ramp MAGiC to 500/month, FDA approval for Synchrony.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Stereotaxis, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $8.6 million, net income ($5.5) million.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $8.6 million
Net income: ($5.5) million
Result: reported results

Exact text from the filing

will increasingly reach development, regulatory and commercial milestones.” 2025 Fourth Quarter and Full Year Financial Results Revenue for the fourth quarter of 2025 totaled $8.6 million, a 36% increase compared to $6.3 million in the prior year fourth quarter. System revenue for the quarter was $3.3 million and recurring revenue was $5.3 million, compared to

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Stereotaxis, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-009366

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.